BioMarin Pharmaceuticals BMRN Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's stock-based comp?
- BioMarin Pharmaceuticals (BMRN) reported stock-based comp of $43.46M in Q1 2026.
- How has BioMarin Pharmaceuticals's stock-based comp changed year-over-year?
- BioMarin Pharmaceuticals's stock-based comp increased by 15.3% year-over-year, from $37.7M to $43.46M.
- What is the long-term trend for BioMarin Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's stock-based comp has grown at a -2.1% compound annual growth rate (CAGR), from $197.26M to $181.41M.
- What does stock-based comp mean?
- The value of stock given to employees as part of their compensation.
- How do you interpret stock-based comp?
- High levels may indicate aggressive talent acquisition or dilution, while low levels may suggest cost discipline.
- How does stock-based comp compare across companies?
- High in the biotech and technology sectors as a standard component of total compensation packages.